-
Study aim
-
In this study, we will examine the effect of dapagliflozin-metformin with two drugs metformin and dapagliflozin in PCOS patients undergoing IVF treatment.
-
Design
-
A randomized, double-arm, parallel-group clinical trial with a design of 80 patients will be enrolled between April 2024 to September 2024.
-
Settings and conduct
-
This study is carried out in Mavold Infertility Clinic, Zahedan University of Medical Sciences Hospital. Patients are placed in the IVF treatment cycle using the gonadotropin-releasing hormone (GNRH) antagonist protocol. The patients in 4 groups received the drugs 2 months before the start of the ovulation cycle, and the drug treatment continued until the day of the puncture of the eggs. Medicines are given to patients by midwives, and both patient and doctor are blinded to the type of medicine.
-
Participants/Inclusion and exclusion criteria
-
Infertility due to polycystic ovary syndrome between the ages of 20 and 42 will be considered as a criterion for entering the study. Hypersensitivity to metformin or SGLT2 inhibitors, presence of other infertility factors, male infertility, congenital adrenal hyperplasia, thyroid gland disorder, Cushing's syndrome, pelvic organ pathology, hyperprolactinemia, androgen-secreting neoplasia, diabetes mellitus or taking drugs that affect carbohydrate metabolism. affects, the use of hormonal analogs other than progesterone two months before the start of the research and severe liver, kidney and pancreatitis diseases or gallstones will be considered as exclusion criteria.
-
Intervention groups
-
Patients are divided into 4 groups (20 people in each group). Group 1: Metformin 2 times a day. Group 2: dapagliflozin twice a day. Group 3: Dapagliflozin - metformin twice a day. Group 4: Placebo twice a day.
-
Main outcome variables
-
Examination of metabolic and hormonal factors, egg and embryo quality